Analysis of SLC16A1/SLC16A3 expression ratio in 205 hematological cancer cell lines, identified 44 cell lines, primarily of lymphoid origin, that are predicted to be sensitive to AZD3965. Here, SLC16A3 is linked to hematopoietic and lymphoid cell neoplasm.